SIRT1. human ortholog of yeast SIR2 protein, deacetylates histories and several other transcription factors . Recently. SIRTI1 has emerged as a drug target for treating age related diseases, type 11 diabetes, neurodegeneration. inflammation and cancer Here, we have optimized production of functionally active wild type full-length SIRT1 protein and its N-terminal deleted mutants In a comparative Study, we found that the region containing 192-208 amino acids towards the N-terminus is critical for right conformational folding of the protein to retain its deacetylase activity The EC50 and IC50 values obtained with standard modulators showed that the SRT748 & SRT556 can deacetylate Substrate and are activated by resveratrol. whereas. deacetylase activity of all the other deletion mutants (SRT540, SRT532, SRT507 and SRT503) Was lost We further report that the peptide Substrate K-m for SRT748 (70 +/- 52 mu M) was comparable to SRT556 (93 +/- 5 4 mu M) The K-m for NAD(+) substrate was 176 & 274 mu M for SRT748 and SRT556. respectively. Similar substrate affinity studies demonstrate that either of the protein (SRT748 or SRT556) can be utilized for screening SIRT1 modulators. We have also examined critical regions in SIRT1 required for deacetylase activity as well as kinetic analyses of SIRT1 proteins. (C) 2009 Elsevier Inc All rights reserved